Sigachi Industries Develops Triple-Drug API Combination for Cystic Fibrosis Treatment
Key Insights
Sigachi Industries (search) has successfully developed a new Active Pharmaceutical Ingredients combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor for cystic fibrosis treatment.
The company estimates a revenue potential of approximately ₹250 crore per annum starting from Q4 FY2026-27, targeting the global cystic fibrosis therapeutics market valued at over $10 billion.
The CF API combination involves advanced chemistry and multi-step synthesis with high technological complexity, creating significant barriers to entry and limiting competitive intensity.
Sigachi Industries (search) has achieved a significant research and development milestone with the successful advancement of a new Active Pharmaceutical Ingredients (APIs) combination for cystic fibrosis treatment. The Hyderabad-based pharmaceutical company announced the development of a triple-drug combination comprising Vanzacaftor, Tezacaftor, and Deutivacaftor, marking an important step in the company's strategic expansion into complex, high-value specialty APIs.
Market Opportunity and Revenue Projections
The development positions Sigachi in the global cystic fibrosis therapeutics market, which is estimated to exceed $10 billion. This market growth is driven by growing adoption of next-generation modulator therapies, long-term treatment requirements, and strong pricing resilience. The company's entry into CF APIs aligns with global demand for advanced therapies in rare and chronic disease segments.
Based on internal market assessment and strategic evaluation, Sigachi estimates a revenue potential of approximately ₹250 crore per annum commencing from Q4 FY2026-27, making this portfolio a meaningful growth driver for the company.
Technical Complexity and Competitive Advantages
The CF API combination involves advanced chemistry, multi-step synthesis, and specialized reactions, resulting in high technological complexity and significant barriers to entry. This complexity limits competitive intensity and reinforces Sigachi's capabilities in complex API manufacturing, positioning the company in what the leadership describes as a "high-entry-barrier specialty segment."
"This milestone reflects Sigachi's focused strategy of building depth in complex and differentiated APIs with long-term growth visibility," said Lijo Chacko, Deputy Group CEO of Sigachi Industries (search). "Our continued investments in R&D and partnerships are aimed at strengthening our position in high-entry-barrier specialty segments and creating sustainable value for stakeholders."
Strategic Partnerships and Long-term Outlook
Sigachi is actively exploring strategic collaborations with formulation innovators for R&D and future commercial supply of these CF APIs. The company's strategic evaluation indicates strong potential for partnerships that could drive the estimated revenue projections, subject to successful partnerships and market progression.
Adding to the long-term commercial opportunity, the innovator patent protection for Vanzacaftor extends until 2039, providing sustained collaboration-led commercial opportunity and revenue stability within the cystic fibrosis therapeutic space. This extended patent protection offers the company a significant competitive advantage and long-term demand visibility in the structurally strong and innovation-led therapeutic segment.